Kwiatkowska Joanna, Budrejko Szymon, Wasicionek Marek, Meyer-Szary F Jarosław, Lubinski Andrzej, Kempa Maciej
Department of Pediatric Cardiology and Congenital Heart Defect, Medical University of Gdansk, Poland.
2nd Department of Cardiology and Electrotherapy, Medical University of Gdansk, Poland.
Adv Clin Exp Med. 2020 Jan;29(1):123-133. doi: 10.17219/acem/110313.
Validation data of the use of implantable cardioverter-defibrillators (ICD) in the pediatric population is insufficient, with limited follow-up periods.
The aim of the study was to report on 17 years of experience with implantable cardioverter-defibrillator (ICD) therapy in children and young adults.
This retrospective review included patients below the age of 18 years at the time of ICD implantation between May 2000 and December 2017. For the statistical analysis, the sample was divided into groups by gender and the type of indications for ICD implantation (primary vs secondary prevention).
The study group included 20 children (8 female, 12 male) who underwent ICD implantation for primary or secondary prevention of sudden cardiac death (SCD). The average age at the time of the initial procedure was 15.6 years (range: 3.8-17.7 years). Primary electrical disease (PED) was present in 9 patients, cardiomyopathy (CMP) in 9 and 2 others had congenital heart defects (CHDs). The median follow-up time was 6.7 years (range: 0.4-12.5 years). The outcomes of ICD therapy were analyzed. No differences between the sexes were found in terms of treatment strategy effectiveness (p > 0.05). The girls were more often treated as primary prevention (p = 0.009). After implantation, all the patients were on optimal pharmacotherapy. Alltogether there were 126 ICD interventions in 11 patients, including 23 inadequate interventions (IA) in 2 children (18.2%).Three children (15%) died due to electrical storms. In the per-procedure analysis, the overall freedom rate from ICD lead replacement was 90%, 80% and 57% at 1, 5 and 10 years of observation, respectively.
Implantable cardioverter-defibrillator implantation indications in children are more heterogeneous in comparison to adult population. In the pediatric population undergoing ICD implantation, the treatment strategy is influenced by gender. The rate of inappropriate ICD discharges (IA) in our group of pediatric patients was low. Rigorous pharmacotherapy and individual ICD programming seemed of paramount importance. Lead malfunctions LF constituted the most prevalent complication observed.
植入式心脏复律除颤器(ICD)在儿科人群中的应用验证数据不足,随访期有限。
本研究旨在报告儿童和青年植入式心脏复律除颤器(ICD)治疗17年的经验。
这项回顾性研究纳入了2000年5月至2017年12月期间接受ICD植入时年龄在18岁以下的患者。为进行统计分析,样本按性别和ICD植入指征类型(一级预防与二级预防)分组。
研究组包括20名儿童(8名女性,12名男性),他们接受ICD植入以一级或二级预防心源性猝死(SCD)。初次手术时的平均年龄为15.6岁(范围:3.8 - 17.7岁)。9例患有原发性电疾病(PED),9例患有心肌病(CMP),另外2例有先天性心脏病(CHD)。中位随访时间为6.7年(范围:0.4 - 12.5年)。对ICD治疗的结果进行了分析。在治疗策略有效性方面未发现性别差异(p > 0.05)。女孩更常接受一级预防治疗(p = 0.009)。植入后,所有患者均接受最佳药物治疗。11例患者共进行了126次ICD干预,其中2名儿童(18.2%)出现23次不适当干预(IA)。3名儿童(15%)死于电风暴。在每次手术分析中,ICD导线更换的总体无事件发生率在观察1年、5年和10年时分别为90%、80%和57%。
与成人相比,儿童植入式心脏复律除颤器的植入指征更为多样。在接受ICD植入的儿科人群中,治疗策略受性别影响。我们这组儿科患者中不适当ICD放电(IA)的发生率较低。严格的药物治疗和个性化的ICD程控似乎至关重要。导线故障是观察到的最常见并发症。